Literature DB >> 23872308

Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance.

Leandro S Thiago1, Martin Perez-Andres, Ana Balanzategui, Maria E Sarasquete, Bruno Paiva, Maria Jara-Acevedo, Paloma Barcena, Maria Luz Sanchez, Julia Almeida, Marcos González, Jesus F San Miguel, Ramón Garcia-Sanz, Alberto Orfao.   

Abstract

The B-cell compartment in which multiple myeloma stem cells reside remains unclear. We investigated the potential presence of mature, surface-membrane immunoglobulin-positive B lymphocytes clonally related to the tumor bone marrow plasma cells among different subsets of peripheral blood B cells from ten patients (7 with multiple myeloma and 3 with monoclonal gammopathies of undetermined significance). The presence of clonotypic immunoglobulin heavy chain gene rearrangements was determined in multiple highly-purified fractions of peripheral blood B-lymphocytes including surface-membrane IgM(+) CD27(-) naïve B-lymphocytes, plus surface-membrane IgG(+), IgA(+) and IgM(+) memory CD27(+) B cells, and normal circulating plasma cells, in addition to (mono)clonal plasma cells, by a highly-specific and sensitive allele-specific oligonucleotide polymerase chain reaction directed to the CDR3 sequence of the rearranged IGH gene of tumor plasma cells from individual patients. Our results showed systematic absence of clonotypic rearrangements in all the different B-cell subsets analyzed, including M-component isotype-matched memory B-lymphocytes, at frequencies <0.03 cells/μL (range: 0.0003-0.08 cells/μL); the only exception were the myeloma plasma cells detected and purified from the peripheral blood of four of the seven myeloma patients. These results indicate that circulating B cells from patients with multiple myeloma and monoclonal gammopathies of undetermined significance are usually devoid of clonotypic B cells while the presence of immunophenotypically aberrant myeloma plasma cells in peripheral blood of myeloma patients is a relatively frequent finding.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23872308      PMCID: PMC4007930          DOI: 10.3324/haematol.2013.092817

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  39 in total

1.  Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation.

Authors:  Pellegrino Musto; Angelo Michele Carella; Michele Mario Greco; Antonietta Falcone; Grazia Sanpaolo; Carlo Bodenizza; Nicola Cascavilla; Lorella Melillo; Angelo Michele Carella
Journal:  Br J Haematol       Date:  2003-11       Impact factor: 6.998

2.  Monoclonal lymphocyte population in human plasma cell myeloma.

Authors:  H Mellstedt; S Hammarström; G Holm
Journal:  Clin Exp Immunol       Date:  1974-07       Impact factor: 4.330

3.  The proliferative potential of myeloma plasma cells manifest in the SCID-hu host.

Authors:  S Yaccoby; J Epstein
Journal:  Blood       Date:  1999-11-15       Impact factor: 22.113

4.  The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells.

Authors:  K Yata; S Yaccoby
Journal:  Leukemia       Date:  2004-11       Impact factor: 11.528

Review 5.  Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

Authors:  J J M van Dongen; A W Langerak; M Brüggemann; P A S Evans; M Hummel; F L Lavender; E Delabesse; F Davi; E Schuuring; R García-Sanz; J H J M van Krieken; J Droese; D González; C Bastard; H E White; M Spaargaren; M González; A Parreira; J L Smith; G J Morgan; M Kneba; E A Macintyre
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

6.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

7.  Characterization of clonogenic multiple myeloma cells.

Authors:  William Matsui; Carol Ann Huff; Qiuju Wang; Matthew T Malehorn; James Barber; Yvette Tanhehco; B Douglas Smith; Curt I Civin; Richard J Jones
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

8.  Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells.

Authors:  Martin Schmidt-Hieber; María Laura Gutiérrez; Martin Pérez-Andrés; Bruno Paiva; Ana Rasillo; Maria Dolores Tabernero; José Maria Sayagués; Antonio Lopez; Paloma Bárcena; María Luz Sanchez; Norma C Gutiérrez; Jesus F San Miguel; Alberto Orfao
Journal:  Haematologica       Date:  2012-08-28       Impact factor: 9.941

9.  Chromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD19+ cells in patients with myeloma and monoclonal gammopathy of undetermined significance.

Authors:  Niklas Zojer; Judith Schuster-Kolbe; Irene Assmann; Jutta Ackermann; Kathrin Strasser; Wolfgang Hübl; Johannes Drach; Heinz Ludwig
Journal:  Br J Haematol       Date:  2002-06       Impact factor: 6.998

10.  Studies on the clonal origin of multiple myeloma. Use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B-cell differentiation.

Authors:  H Kubagawa; L B Vogler; J D Capra; M E Conrad; A R Lawton; M D Cooper
Journal:  J Exp Med       Date:  1979-10-01       Impact factor: 14.307

View more
  12 in total

1.  Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis.

Authors:  M Gkotzamanidou; E Terpos; C Bamia; S A Kyrtopoulos; P P Sfikakis; M A Dimopoulos; V L Souliotis
Journal:  Leukemia       Date:  2013-10-03       Impact factor: 11.528

Review 2.  New criteria for response assessment: role of minimal residual disease in multiple myeloma.

Authors:  Bruno Paiva; Jacques J M van Dongen; Alberto Orfao
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

3.  A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma.

Authors:  Barbara Muz; Pilar de la Puente; Feda Azab; Micah John Luderer; Justin King; Ravi Vij; Abdel Kareem Azab
Journal:  Br J Haematol       Date:  2016-01-05       Impact factor: 6.998

Review 4.  The myeloma stem cell concept, revisited: from phenomenology to operational terms.

Authors:  Hans Erik Johnsen; Martin Bøgsted; Alexander Schmitz; Julie Støve Bødker; Tarec Christoffer El-Galaly; Preben Johansen; Peter Valent; Niklas Zojer; Els Van Valckenborgh; Karin Vanderkerken; Mark van Duin; Pieter Sonneveld; Martin Perez-Andres; Alberto Orfao; Karen Dybkær
Journal:  Haematologica       Date:  2016-11-10       Impact factor: 9.941

5.  Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination.

Authors:  Juan-Jose Garcés; Michal Simicek; Marco Vicari; Lucie Brozova; Leire Burgos; Renata Bezdekova; Diego Alignani; Maria-Jose Calasanz; Katerina Growkova; Ibai Goicoechea; Xabier Agirre; Ludek Pour; Felipe Prosper; Rafael Rios; Joaquin Martinez-Lopez; Pamela Millacoy; Luis Palomera; Rafael Del Orbe; Albert Perez-Montaña; Sonia Garate; Laura Blanco; Marta Lasa; Patricia Maiso; Juan Flores-Montero; Luzalba Sanoja-Flores; Zuzana Chyra; Alexander Vdovin; Tereza Sevcikova; Tomas Jelinek; Cirino Botta; Halima El Omri; Jonathan Keats; Alberto Orfao; Roman Hajek; Jesus F San-Miguel; Bruno Paiva
Journal:  Leukemia       Date:  2019-10-08       Impact factor: 11.528

6.  Mass cytometry analysis shows that a novel memory phenotype B cell is expanded in multiple myeloma.

Authors:  Leo Hansmann; Lisa Blum; Chia-Hsin Ju; Michaela Liedtke; William H Robinson; Mark M Davis
Journal:  Cancer Immunol Res       Date:  2015-02-20       Impact factor: 11.151

7.  Three-dimensional Nuclear Telomere Organization in Multiple Myeloma.

Authors:  Ludger Klewes; Rhea Vallente; Eric Dupas; Carolin Brand; Dietrich Grün; Amanda Guffei; Chirawadee Sathitruangsak; Julius A Awe; Alexandra Kuzyk; Daniel Lichtensztejn; Pille Tammur; Tiiu Ilus; Anu Tamm; Mari Punab; Morel Rubinger; Adebayo Olujohungbe; Sabine Mai
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

8.  Detection of monoclonal IGH rearrangements in circulating cells from healthy first-degree relatives of patients with multiple myeloma.

Authors:  Herbert García-Castillo; Evelia Leal-Ugarte; Pablo César Ortiz Lazareno; Esperanza Barrera-Chairez; Víctor Hugo Rosales-García; Patricio Barros-Núñez
Journal:  Med Oncol       Date:  2014-03-01       Impact factor: 3.064

Review 9.  A replicative self-renewal model for long-lived plasma cells: questioning irreversible cell cycle exit.

Authors:  Reuben M Tooze
Journal:  Front Immunol       Date:  2013-12-18       Impact factor: 7.561

10.  Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow.

Authors:  Leo Hansmann; Arnold Han; Livius Penter; Michaela Liedtke; Mark M Davis
Journal:  Cancer Immunol Res       Date:  2017-08-02       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.